3:58 PM
 | 
Feb 28, 2019
 |  BC Innovations  |  Emerging Company Profile

Gotham’s RNA utility belt

Gotham enters RNA epigenetics with atomic-level screening system

Editor's Note: This article was updated on Mar 01, 2019 at 8:54 AM PST

Gotham Therapeutics Corp., the newest comer to the RNA epigenetics party, delves into the atomic-level biophysical properties of RNA-modifying enzymes to accelerate its small molecule discovery programs for cancer and other diseases.

RNA epigenetics is a growing area of research that spawned Storm Therapeutics Ltd. in 2016 and Accent Therapeutics Inc. and Gotham in 2017 (see “Accent on RNA” ; “Taking RNA Epigenetics by Storm”).

Co-founded by Versant Ventures, Weill Cornell Medicine professor Samie Jaffrey, CEO Lee Babiss, CSO Gerhard Mueller and COO Birgit Zech, Gotham emerged from stealth with a $54 million series A in October (see “Versant Seizes the RNA Moment”).

Babiss told BioCentury that while RNA epigenetic enzymes mirror their DNA counterparts, comprising readers, writers and erasers, the RNA epigenetic field is a “whole new area of...

Read the full 646 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >